The lower figure is realistic if NTM comes in big and Euro CF/Pa facilitiates an FDA filing. That is a market cap of $625 megs on two orphan indications. Just like Increlex was for the TRCA buyout back in 2007. But INSM will not have the problem TRCA/Ipsen had of simply making the stuff. Liposomal drugs are easy to manufacture. Fourty years of capability, cheap, etc. Complex biologicals (recombinant or proteonomic) are a coin flip. Ipsen was back to the position of TRCA where Lonza was throwing away every other batch. That costs $ millions. When WL starts talking about the second generation liposome product, then the higher figure of $50 per share takes on credibility. But with only the speculation from PPs, it is not real.